RESEARCH



Disability level's impact on blood pressuremortality association in older long-term care adults: evidence from a large Chinese cohort study

Yue Zhong^{1†}, Chuanteng Feng^{2,3†}, Lisha Hou⁴, Ming Yang⁴, Xinjun Zhang⁴, Jinhui Wu⁴, Birong Dong⁴, Peng Jia^{5,6}, Shujuan Yang^{3,6*} and Qingyu Dou^{4,7*}

Abstract

Background Evidence of the optimal blood pressure (BP) target for older adults with disability in long-term care is limited. We aim to analyze the associations of BP with mortality in older adults in long-term care setting with different levels of disability.

Methods This prospective cohort study was based on the government-led long-term care programme in Chengdu, China, including 41,004 consecutive disabled adults aged ≥ 60 years. BP was measured during the baseline survey by trained medical personnel using electronic sphygmomanometers. Disability profile was assessed using the Barthel index. The association between blood pressure and mortality was analyzed with doubly robust estimation, which combined exposure model by inverse probability weighting and outcome model fitted with Cox regression. The non-linearity was examined by restricted cubic spline. The primary endpoint was all-cause mortality, and the secondary endpoints were cardiovascular and non-cardiovascular mortality.

Results The associations between systolic blood pressure (SBP) and all-cause mortality were close to a U-shaped curve in mild-moderate disability group (Barthel index \geq 40), and a reversed J-shaped in severe disability group (Barthel index < 40). In mild-moderate disability group, SBP < 135 mmHg was associated with elevated all-cause mortality risks (HR 1.21, 95% Cl, 1.10–1.33), compared to SBP between 135 and 150 mmHg. In severe disability group, SBP < 150 mmHg increased all-cause mortality risks (HR 1.21, 95% Cl, 1.16–1.27), compared to SBP between 150 and 170 mmHg. The associations were robust in subgroup analyses in terms of age, gender, cardiovascular comorbidity and antihypertensive treatment. Diastolic blood pressure (DBP) < 67 mmHg (HR 1.29, 95% Cl, 1.18–1.42) in mild-moderate disability group and < 79 mmHg (HR 1.15, 95% Cl, 1.11–1.20) in severe disability group both demonstrated an increased all-cause mortality risk.

Conclusion The optimal SBP range was found to be higher in older individuals in long-term care with severe disability (150-170mmHg) compared to those with mild to moderate disability (135-150mmHg). This study provides new

[†]Yue Zhong and Chuanteng Feng contributed equally to this work.

*Correspondence: Shujuan Yang rekiny@126.com Qingyu Dou ddqqking@126.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

evidence that antihypertensive treatment should be administered cautiously in severe disability group in long-term care setting. Additionally, assessment of disability using the Barthel index can serve as a valuable tool in customizing the optimal BP management strategy.

Trial registration Chinese Clinical Trial Registry (Registration Number: ChiCTR2100049973).

Keywords Older adults, Disability, Blood pressure, Long-term care

Background

Hypertension stands as one of the most widespread diseases among the older adults, affecting approximately 60% of individuals aged over 60 [1, 2]. With the pace of population ageing accelerating [3], more than half of older individuals grapple with disabilities in activities of daily living (ADL), which is a significant health issue among older adults [4, 5]. Unfortunately, this particular demographic is often excluded from randomized controlled trials (RCT) focused on antihypertensive treatment for older adults [6-8]. Studies like SPRINT (Systolic Blood Pressure Intervention Trial) and the recent STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) trial have demonstrated the benefits of intensive blood pressure (BP) control for older patients [9, 10]. But these data only represent as few as one third of older adults in the general population, since they excluded patients with multimorbidity or functional loss [7, 11], raising the need for research specifically focus on this unique group.

recommend Current guidelines individualized treatment approaches for older individuals with impaired function, but the detailed BP target for this group is lack of evidence [12–15]. On one hand, some observational cohort studies focusing on the oldest individuals have revealed that both lower and higher systolic BP (SBP) levels (<120 mmHg and >165 mmHg) are associated with increased mortality risk, presenting a J- or U-shaped association [16-18]. On the other hand, there have been suggestions that elevated SBP (>140 mmHg) does not lead to excess mortality. In fact, it may even be inversely correlated with an increased risk of death in older individuals with poor functioning [19, 20]. These conflicting findings may stem from the varying degrees of disability in the above studies, which potentially change the association between BP and mortality.

Given the ethical constraints associated with conducting RCTs in older individuals with functional disabilities, real-world data emerges as a crucial resource to bridge the evidence gap for personalized treatment. This current study draws upon the government-backed Chengdu Long-Term Care Insurance (LTCI) cohort, encompassing older individuals with varying degrees of ADL disability who applied for LTCI since 2017 [21]. Our objectives were to investigate the non-linear association between BP levels and mortality in older adults with ADL disability in government-backed long-term care setting, and to evaluate how different profiles of disability could change the association between BP and the risks of all-cause mortality as well as cause-specific mortality.

Methods

Study design

This is a prospective open cohort study. The participants were enrolled from the government-led LTCI programme in Chengdu, initiated on September 27th, 2017, and overseen by the Chengdu Healthcare Security Administration [21]. The inclusion criteria were: (1) older adults requiring long-term care, with sustained loss of ADL independence persisting for over 6 months, irreversibly unresponsive to rehabilitation, and (2) possess urban medical insurance [21]. The Chinese government promotes a long-term care system with home-based care as its cornerstone, complemented by community-based services and institutional care. Under the support of LTCI, care is provided in two manners: (1) home care by a family member with home visits from a nursing home supporter, and (2) institutional care in a nursing home. Initially, a total of 44,258 participants were enrolled. Exclusions comprised individuals below the age of 60 and those with functional disabilities resulting from trauma. Each participant was tracked from their entry date to either the date of decease or August 2nd, 2021, whichever came first. Ultimately, a cohort of 41,004 individuals aged 60 and above were recruited between September 27th, 2017, and August 2nd, 2021 (Supplemental Fig. S1). The study received ethical approval from the institutional ethics review committee of West China Hospital (2017 - 303) and was registered at the Chinese Clinical Trial Registry (Registration Number: ChiCTR2100049973, Date: 15/08/2021). The study adhered to the Helsinki Declaration of 1964. Written informed consent was obtained from all participants or their legal representatives.

Outcomes

The primary outcome was all-cause mortality. Data regarding deaths were sourced from the national medical insurance systems, which were linked to the electronic medical records and corresponding death certificates.

Secondary outcomes were cardiovascular and noncardiovascular mortalities, which were classified in accordance with the International Classification of Diseases, 10th revision (ICD-10 codes: I10-I15, I20-I25, I30-I52, I60-I79, and I95-I99, representing cardiovascular mortality).

Measurement of blood pressure

The primary predictor variable was BP. At the time of applying for LTCI, the government will send trained medical workers to assess the functional status of the applicants. The vital signs including BP was assessed during this baseline survey. BP was measured by Omron electronic sphygmomanometer (HEM7122 and HEM7124). These measurements followed the standardized BP measurement protocol outlined in established guidelines [12, 14, 15]. Prior to use, the electronic sphygmomanometers were calibrated, and all investigators underwent uniform training. For each participant, three accurate BP readings were taken on the right arm in a rested state. These readings were then averaged to calculate both the SBP and diastolic BP (DBP). In cases where participants were bedbound, BP measurements were obtained in a recumbent position.

Measurement of disability profiles

A structured face-to-face interview was conducted by trained investigators, during which information was gathered from participants or their caregivers. The entire evaluation process was recorded on video, and a committee overseeing the LTCI programme was entrusted with the assessment. The participants' disability profiles were assessed by the Barthel index, a widely recognized instrument for measuring performance in basic ADL [22]. This index encompasses 10 essential daily activities, including feeding, bathing, grooming, dressing, bowel and bladder control, toilet use, steps, transfer and mobility. Scores range from 0 to 100 points. According to the current policy of China's LTIC programme, severe disability was determined as the Barthel index < 40), while mild to moderate disability was the index \geq 40 [21]. This criterion is consistent with the standardized disability assessment criteria used across the 15 LTCI cities in China [21]. Validation study indicated with a Barthel score < 40, no one was independent in the mobility skills and fewer than 50% were independent in the very basic skills [23].

Covariates

Covariates were meticulously gathered through a standardized face-to-face questionnaire and physical examination, and the diagnosis of chronic disease was confirmed by related medical records. When the disabled

older adults applied for LTCI, they were required to provide official medical records detailing their medical history and condition as proof. Demographic characteristics included age, gender, education level, and marital status. Participants' care mode was classified as either home-based or institutional. Comorbidities included coronary artery disease, heart failure, chronic obstructive pulmonary disease, cerebrovascular disease, diabetes, chronic kidney disease at stages 3 to 5, and cancers. The comorbidity score was assessed using the Charlson comorbidity index [24]. The diagnosis of hypertension is confirmed by diagnosis certificates from medical institutions or current use of antihypertensive medication. Information regarding antihypertensive drug treatment at baseline was collected from the latest medical records, as well as the laboratory indicators including total cholesterol, fasting plasma glucose, serum creatinine, and blood uric acid. The cognitive impairment and perception impairment were evaluated by the cognitive and sensory perception assessment scale, as previously reported [25]. The scale demonstrated a credible level of internal consistency, with a Cronbach's alpha coefficient of 0.91. The cognitive impairment assessment focused on memory and concentration abilities, while perception impairment evaluation encompassed vision, hearing, and communication capacities.

Statistical analyses

Continuous variables were presented as mean and standard deviation, while categorical variables as numbers and percentages. Baseline data between the two disability groups were compared using t-tests or χ^2 tests. The measure of person-years is the cumulative survival time of all the participants during our follow-up. Inverse propensity weighting was used to balance the distribution of baseline covariates in subsequent analyses. The study employed a doubly robust approach to evaluate the non-linear association between the BP levels and mortality risk. This entailed employing an exposure model through inverse probability weighting, and an outcome model fitted with a Cox regression model and restricted cubic splines [26, 27]. Both SBP and DBP were treated as continuous variables to assess their nonlinear association with all-cause mortality, as well as cardiovascular and non-cardiovascular mortality. Reference points were defined as 150 mmHg for SBP and 90 mmHg for DBP, based on significant benefits observed in prior RCT upon lowering SBP to <150 mmHg in older adults [6]. Restricted cubic splines were employed to graphically estimate potential nonlinear associations between BP and mortality in the

weighted samples. For the non-linear trend, we defined a 'U-shaped' curve as a basically symmetrical shape across the nadir with increasing mortality risk at both higher and lower levels of BP, while a 'reversed J-curve' was characterized by an asymmetrical shape with an augmentation of mortality risk with decreasing BP from the nadir [28]. The cut-off points were determined by the intersections of the 95% confidence intervals (CI) of mortality risk with the abscissa where hazard ratio (HR) was 1. Subsequently, BP values were categorized into ranges based on the identified cut-off points. Cox proportional hazards models, adjusted for the aforementioned covariates, were utilized to estimate the association between BP ranges and mortality. Fine-Gray competing models were employed to assess the association between categorical SBP and DBP with cause-specific mortality, in consideration of potential competing risks [29].

Subgroup analyses were conducted among: (1) participants aged 60 to 80 years and those over 80 years; (2) males and females; (3) individuals with and without antihypertensive treatment; (4) individuals with and without cardiovascular comorbidity; and (5) individuals with comorbidity scores exceeding and not exceeding the median level. Categorical BP ranges derived from restricted cubic splines were assessed in all models. Furthermore, Cox regression with interaction terms was used to test for significance of differences between subgroups. Sensitivity analyses including: (1) stratification of participants based on every 10-mmHg increment of the BP value; (2) exclusion of participants with a follow-up period < 6 months to preclude excessively low BP values influenced by terminal phases; (3) exclusion of participants with cancer, given their typically abbreviated survival periods; and (4) fitting of Cox proportional-hazards regression models without doubly robust estimators.

The threshold for statistical significance was set at a two-sided p < 0.05 for all analyses. The statistical software R (Version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria) was employed for all analyses.

Results

Participant characteristics

At baseline, the mean age of the 41,004 participants was 80.8 ± 9.1 years, with females comprising 57.1% (23,415) of the cohort. Table 1 provides a comprehensive description of participant characteristics. 71% of the participants (29,133) received home-based care. Notably, the mild-moderate disability group exhibited significantly higher levels of both SBP and DBP compared to those with severe disability. Over a median follow-up period of 14.2 months, a total of 17,797 participants (43.4%) died. Among these, 5,739 individuals died from cardiovascular causes, while 12,058 deaths were attributed to noncardiovascular causes. The primary reasons for noncardiovascular mortality were respiratory failure, infectious diseases and malnutrition related diseases.

Association of BP with all-cause mortality risk

The mild-moderate disability group exhibited a mortality rate of 18.7 per 100 person-years, while the severe disability group had a higher rate of 32.3 per 100 personyears. Among the mild-moderate disability group, we observed a nearly U-shaped curve (p < 0.001 for nonlinear association) in the association between SBP and all-cause mortality. While a reversed J-curve was found among the severe disability group (p < 0.001 for non-linear association) (Fig. 1).

For the mild-moderate disability group, with 150 mmHg selected as the reference point, 135 mmHg was identified as the intersection of the 95% CI with the abscissa. Those with SBP < 135 mmHg exhibited a significantly increased risk of mortality, with the HR escalating from 1.06 (95% CI 1.01-1.13) at 135 mmHg to 1.54 (95% CI, 1.38-1.74) at 100 mmHg. In the severe disability group, 170 mmHg marked the intersection of the 95% CI with the abscissa. When compared to 150 mmHg, SBP of 150-170 mmHg showed a slightly lower risk of mortality [HR (95% CI) at 160 mmHg: 0.98 (0.97-0.99)] (Fig. 1 and Supplemental Fig. S2). The association of DBP with all-cause mortality is depicted in Supplemental Fig. S3, where a reversed J-shaped association was observed in both the mild-moderate disability and severe disability groups.

The comparisons of the optimal BP ranges are detailed in Table 2. The middle ranges of BP derived from the cubic spline were the reference points. Compared with SBP of 135–150 mmHg, the mild-moderate disability group with SBP < 135 mmHg demonstrated an increased adjusted mortality risk (HR 1.21, 95% CI, 1.10–1.33). In severe disability group, SBP < 150 mmHg was associated with an elevated mortality risk (HR 1.21, 95% CI, 1.16–1.27) compared to SBP of 150–170 mmHg. Furthermore, DBP < 67 mmHg (HR 1.29, 95% CI, 1.18–1.42) in the mild-moderate disability group and <79 mmHg (HR 1.15, 95% CI, 1.11–1.20) in severe disability group demonstrated an increased all-cause mortality risk. When BP values were divided by 10 mmHg, similar trends were observed as in the main analysis (Supplemental Table S1).

Association of BP with cause-specific mortality risk

For cardiovascular mortality, in the mild-moderate disability group, SBP displayed a J-shaped association, whereas in the severe disability group, a reversed

F	² age	5	of	1	2

Characteristics	All participants (n=41,004)	Mild-moderate disability (n=8,135)	Severe disability (n=32,869)	<i>p</i> value**
Demographics				
Age (year)	80.75 ± 9.06	79.34±9.23)	81.09±8.99	< 0.001
Female sex	23,415 (57.1)	4,376 (53.8)	19,039 (57.9)	< 0.001
Educational level				0.002
Primary school or below	26,270 (64.1)	5330 (65.5)	20,940 (63.7)	
Middle school or above	14,734 (35.9)	2805 (34.5)	11,929 (36.3)	
Marriage status				< 0.001
In marriage	22,060 (53.8)	4,730 (58.1)	17,330 (52.7)	
Never married, widowed, or divorced	18,944 (46.2)	3,405 (41.9)	15,539 (47.3)	
Care mode				< 0.001
Home based	29,133 (71.0)	6,593 (81.0)	22,540 (68.6)	
Institutional based	11,871 (29.0)	1,542 (19.0)	10,329 (31.4)	
Antihypertensive drugs use				0.001
Yes	24,099 (58.8)	4,908 (60.3)	19,191 (58.4)	
No	16,905 (41.2)	3227 (39.7)	13,678 (41.6)	
Total cholesterol (mmol/L)*	5.22±2.54	5.16±2.17	5.23 ± 2.64	0.096
Fasting plasma glucose (mmol/L)*	6.23 ± 3.82	6.33±3.78	6.20 ± 3.83	0.058
Serum creatinine (µmol/L)*	92.31±46.71	92.94±49.69	92.12±45.81	0.332
Blood uric acid*	384.68±166.04	386.62±155.21	384.11±169.06	0.358
Chronic conditions				
Coronary artery disease	10,199 (24.9)	1,941 (23.9)	8,258 (25.1)	0.019
Heart failure	4,567 (11.1)	859 (10.6)	3,708 (11.3)	0.067
Chronic obstructive pulmonary disease	12,609 (30.8)	2,451 (30.1)	10,158 (30.9)	0.179
Cerebrovascular disease	20,857 (50.9)	3,851 (47.3)	17,006 (51.7)	< 0.001
Diabetes mellitus	10,858 (26.5)	2,225 (27.4)	8,633 (26.3)	0.048
Chronic kidney disease stages 3–5	4,783 (11.7)	1,019 (12.5)	3,764 (11.5)	0.007
Cancer	2,156 (5.3)	414 (5.1)	1,742 (5.3)	0.463
Cognitive impairment				< 0.001
Robust	1,588 (3.9)	689 (8.5)	899 (2.7)	
Mild impairment	12,304 (30.0)	3,414 (42.0)	8,890 (27.0)	
Moderate impairment	19,248 (46.9)	3,264 (40.1)	15,984 (48.6)	
Severe impairment	7,864 (19.2)	768 (9.4)	7,096 (21.6)	
Perception impairment				<0.001
Robust	4,421 (10.8)	2,130 (26.2)	2,291 (7.0)	
Mild impairment	20,602 (50.2)	4,937 (60.7)	15,665 (47.7)	
Moderate impairment	14,388 (35.1)	1,043 (12.8)	13,345 (40.6)	
Severe impairment	1,593 (3.9)	25 (0.3)	1,568 (4.8)	
Systolic blood pressure (mmHg)	137.04±25.24	143.14 ± 25.22	135.53 ± 25.01	< 0.001
Diastolic blood pressure (mmHg)	76.58±15.30	79.15±14.76	75.94±15.37	< 0.001
Charlson comorbidity index	2.15 ± 1.74	2.11±1.73	2.16 ± 1.74	0.007

Table 1 Baseline characteristics of the participants from the long-term care program in Chengdu grouped by disability status

Data was expressed as mean ± standard deviation for continuous variables, and as number (%) for categorical variables

*Data missing in this line, n = 4,321 for mild-moderate disability group, n = 14,876 for severe disability group

**Significant p values were shown in bold. The two disability groups were compared by t-tests or χ^2 tests as appropriate




Fig. 1 Cox models with cubic restricted splines of the association between systolic blood pressure and all-cause mortality risk stratified by disability status (reference: 150 mmHg). U-shaped association was observed in mild-moderate disability group, and reversed J-shaped in severe disability group. Hazard ratio was adjusted for age, sex, education, marital status, care modes, multimorbidity, cognitive impairment and perception impairment

Table 2	Association of I	blood	pressure range with	h all-cause mortali	ity risk stratifiec	by disability status

Blood pressure values	N 6		All-cause mortality			
	No. of Participants	No. of deaths	Unadjusted HR (95% CI)	Adjusted HR (95% CI)		P values
Mild-moderate disability group					-	P values
Systolic blood pressure, mmHg						
Lower (<135 mmHg)	3,077	1,159	1.29 (1.17, 1.41)	1.21 (1.10, 1.33)		< 0.001
Middle (135-150mmHg)	2,131	708	1.00	1.00	•	reference
Higher (>150 mmHg)	2,927	963	0.94 (0.85, 1.03)	0.97 (0.88, 1.07)		0.521
Diastolic blood pressure, mmHg						0.021
Lower (< 67 mmHg)	1,588	728	1.47 (1.35, 1.61)	1.29 (1.18, 1.42)		< 0.001
Middle (67-90mmHg)	4,964	1,651	1.00	1.00	+	reference
Higher (> 90 mmHg)	1,583	451	0.83 (0.75, 0.93)	0.99 (0.89, 1.11)		0.927
Severe disability group						
Systolic blood pressure, mmHg						
Lower (<150 mmHg)	24,029	11,411	1.30 (1.24, 1.36)	1.21 (1.16, 1.27)	+=-1	< 0.001
Middle (150-170mmHg)	6,070	2,487	1.00	1.00	-	reference
Higher (> 170mmHg)	2,770	1,069	0.92 (0.85, 0.98)	0.95 (0.87, 1.02)	F	0.174
Diastolic blood pressure, mmHg						
Lower (<79 mmHg)	19,345	9,571	1.27 (1.22, 1.32)	1.15 (1.11, 1.20)	H B -I	< 0.001
Middle (79 - 90mmHg)	8,771	3,653	1.00	1.00	•	reference
Higher (>90 mmHg)	4,753	1,743	0.88 (0.83, 0.93)	1.00 (0.94, 1.06)		0.947

HR values were shown in bold if significant difference

J-shaped association was observed (Fig. 2). Specifically, compared to those with SBP of 150-170 mmHg, individuals in the severe disability group with SBP < 150 mmHg exhibited a significantly higher cardiovascular mortality risk (HR 1.14, 95% CI, 1.06–1.24). Conversely, in the mild-moderate disability group, SBP < 135 mmHg

conveyed no significant cardiovascular mortality risk (Fig. 2 and Supplemental Table S2). Additionally, when BP was categorized in 10 mmHg increments, lower SBP levels in the severe disability group were still significantly associated with increased cardiovascular mortality risk (Supplemental Table S3).

The association between SBP and non-cardiovascular mortality risk presented a reversed J-shaped curve in the mild-moderate disability group. While in the severe disability group, there was a negative correlation with increasing SBP (Fig. 2). Specifically, mild-moderate disability participants with SBP < 135 mmHg showed an increased non-cardiovascular mortality risk (HR 1.31,

95% CI, 1.17–1.47) compared to SBP of 135–150 mmHg (Supplemental Table S2). Furthermore, DBP < 79 mmHg in the severe disability group (HR 1.17, 95% CI, 1.11–1.23), as well as DBP < 67 mmHg in the mild-moderate disability group (HR 1.41, 95% CI, 1.27–1.57), were associated with an increased non-cardiovascular mortality risk. When BP was categorized in 10 mmHg increments,




Fig. 2 Cox model with cubic restricted splines analysis of systolic blood pressure with cardiovascular and non-cardiovascular mortality risk stratified by disability status (reference: 150 mmHg). Hazard ratio was adjusted for age, sex, education, marital status, care modes, multimorbidity, cognitive impairment and perception impairment

lower SBP levels were associated with increased non-cardiovascular mortality risk in both groups (Supplemental Table S4).

Subgroup and sensitivity analyses

The subgroup analyses corroborated the main findings. No significant interactions were identified between SBP and all-cause mortality by subgroups defined by age, gender, antihypertensive treatment, cardiovascular morbidity, or the severity of comorbidity (all interaction p > 0.05, Supplemental Fig. S4). Notably, the use of antihypertensive drug did not alter the observed association between SBP and mortality (Fig. 3). Both SBP < 135 mmHg in the mild-moderate disability group and SBP < 150 mmHg in the severe disability group were associated with increased all-cause mortality risk across the subgroups (Supplemental Fig. S4). Additionally, the inflection points of mortality risk were generally lower than 150 mmHg in the mild-moderate disability subgroups and higher than 150 mmHg in the severe disability subgroups, indicating that the safe BP range for the severe disability group was consistently higher than that for the mild-moderate group (Supplemental Fig. S5).

When the model without doubly robust estimators was employed, the severe disability group exhibited a more pronounced decrease in the reverse J-shaped curve depicting the association between SBP and all-cause mortality. Minor variations were observed when participants with a follow-up period < 6 months and those with cancer were excluded in sensitivity analyses (Supplemental Fig. S6).

Discussion

In this large open cohort study, we observed that disability status modified the association between SBP and mortality risk in long-term care settings. Older individuals with mild-moderate disability demonstrated a nearly U-shaped association between SBP and all-cause mortality, while those with severe disability exhibited a reversed J-shaped association. Specifically, SBP ranges of 135-150 mmHg for the mild-moderate disability group and 150-170 mmHg for the severe disability group were identified as reasonable blood pressure targets. Lower BP (SBP < 135mmHg, DBP < 67mmHg in the mild-moderate disability group and SBP < 150mmHg, DBP < 79mmHg severe disability group) was associated in the with an increased risk of mortality, irrespective of antihypertensive medication status. This study has taken into account competing risks and was additionally validated through sensitivity analyses. These results implied the significance of assessing disability profiles by the Barthel index in tailoring individualized BP control strategies for older individuals in long-term care setting.

Optimal BP range for older adults with disability

The optimal BP range might be higher for disabled older adults in long-term care than for the community-dwelling older population. Previous community-based cohort studies for individuals aged between 75 and 90 years old demonstrated that SBP < 110-125 mmHg correlated with increased mortality [18, 30, 31]. In our study, SBP lower than 135 mmHg increased all-cause mortality in mild-moderate disabled participants. Furthermore, for our severe disability group, the safe SBP range was 150-170 mmHg. The optimal SBP target would change with functional status, as fibrosis of the heart and other vital organ is implicated with aging [32]. A relatively higher BP level was supposed to maintain adequate organ perfusion, such as the brain, heart, and kidneys, especially in individuals with impaired functional status and multimorbidity [33]. The benefit of antihypertensive treatment in older patients decreased with the deterioration of clinical status [34]. In addition, there is extensive documentation regarding the heightened susceptibility of older adults with functional decline to treatment-related drug side effects [35]. Importantly, our study is the first to suggest that older adults with severe disability may require a higher BP level and less aggressive antihypertensive treatment than those with mild-moderate disability. Antihypertensive treatment should be administered cautiously in this special severe disability group to avoid iatrogenic-induced problems in long-term care settings.

Lower BP with all-cause mortality and cause-specific mortality

Our study underscores the significance of paying attention to the association between lower BP and heightened all-cause mortality in long-term care settings. Similarly, the PARTAGE study with individuals over 80 years old in institutional care showed an inverted association between increased SBP and all-cause mortality [36]. In a Swedish cohort comprising nursing home residents \geq 65 years old, SBP < 120 mmHg was linked to elevated all-cause mortality, regardless of the use of antihypertensive medications [37]. Reduced BP is thought to be an indicator of a more advanced neurodegenerative process [38]. This explains why severe disability older adults have lower baseline BP compared to those with mild-moderate disability. It is noteworthy that the number of non-cardiovascular deaths was 2.1 times that of cardiovascular deaths in our study. This finding aligns with previous research indicating that in older adults with disabilities, the risk of non-cardiovascular mortality, particularly respiratory and infection-related deaths, may outweigh that of cardiovascular risk [39]. These results suggest that the




Fig. 3 The association between SBP and all-cause mortality in participants with and without antihypertensive drug use

association between lower SBP and increased risk of mortality among severely disabled older individuals is largely driven by non-cardiovascular mortality. Our data additionally indicate that higher SBP-related cardiovascular mortality have a restricted influence on overall mortality in severe disability older adults. This could be attributed to the intricate nature of co-existing comorbidities [40]. Consequently, our findings suggest that addressing non-cardiovascular morbidities may hold relatively greater significance for severe disabled older adults.

Previous research has proposed that reverse causation, wherein lower BP result from proximity to death, might contribute to the association between low BP and mortality [41]. However, another investigation demonstrated that, in a long-term care setting, SBP levels remained stable until the last 3–4 weeks of life [42]. Considering the median follow-up period in our current study, which exceeds 14.2 months, it is improbable that the observed associations are solely attributed to terminal BP decline or reverse causation. The sensitivity analysis excluding individuals who died within a 6-month period after admission further validated these findings. Future studies employing randomized interventions could help to gain a deeper understanding of this causal relationship.

Modification effect of disability on the optimal BP range for older adults

In our study, the associations between BP and mortality risk among older adults exhibited variation according to their ADL disability status. We hypothesized that decline of biological function attenuated the correlation between elevated SBP and mortality risk. This modification effect of disability profile on the association between BP and mortality remained robust across subgroups and was independent of chronological age in our investigation. In addition, no significant interaction was found between age and SBP-mortality association, suggesting that the modification effect was mostly attributed to the ADL disability status. Biological aging process accompanied by functional dependence is more important than chorological aging in comprehensive geriatric assessments [43].

Prior studies about the association between BP and mortality in older populations using frailty measures have yielded mixed findings [44]. Some studies observed that gait speed could either alter or leave unaffected the link between SBP and mortality risk [20, 45]. Additionally, the modification effect of frailty assessed by the electronic frailty index on the association between SBP and mortality was only evident in the age group of 85 years and older [19]. The diverse measures to define frailty status across different studies may weaken the comparability of their results. Frailty is more of a reversible condition than disability [46]. Older adults who were frail but without disability had no increased risk for mortality or nursing home admission [47]. Disability may manifest later than frailty in the hierarchical continuum of the aging process and tends to be more stable over time [48]. Our study highlights that biological aging, as reflected by the degree of disability assessed through the Barthel index scores, exerts a substantial modification effect on the association between BP and mortality risk.

Strengths and limitations

This study had several noteworthy strengths. By doubly robust analysis, we minimized bias effect in the estimation of mortality risk. Inverse propensity weighting was utilized to balance the distribution of baseline covariates across diverse BP exposure groups. Second, through data-driven methods and this large-scale long-term care cohort, we conducted a thorough exploration for the effect of disability profile on the association between BP and mortality. By the advantage of large sample size, our study provided valuable evidence for tailoring BP management in disabled older adults in the long-term care setting.

However, certain limitations should be acknowledged. Firstly, given that our participants were drawn from the LTCI, the number of severely disabled individuals considerably outweighed that of the mild-moderately disabled, potentially introducing selection bias. Secondly, data on changes in BP during follow-up were not available, preventing us from discerning the impact of BP variability on mortality. Thirdly, for some bedbound participants, the measurement of BP in recumbent position may result in slightly higher SBP and lower DBP readings compared to seated measurements [49]. Further investigations are warranted to explore the association between longitudinal BP fluctuations and mortality among older individuals.

Conclusion

This prospective cohort study contributes further evidence regarding the increased mortality associated with low BP among older residents in long-term care settings. Furthermore, our study suggests that the disability profile modifies the associations between BP and mortality risk in older adults. A higher optimal BP range was observed in older individuals in long-term care with severe disability compared to those with mild-moderate disability. The assessment of disability using the Barthel index can serve as a valuable tool in customizing the optimal BP management strategy for long-term care older adults. The management of hypertension in long-term care residents should not be simply extrapolated from evidence obtained in older adults residing in the community.

Abbreviations

- BP Blood pressure
- LTCI Long-term care insurance
- ADL Activities of daily living SBP Systolic blood pressure
- SBP Systolic blood pressure DBP Diastolic blood pressure

.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12877-024-05094-y.

Supplementary Material 1.

Acknowledgements

We thank Chengdu Healthcare Security Administration.

Authors' contributions

YZ, CF contributed to the study design, data analysis, and drafted the manuscript. LH, MY and PJ contributed to the data analysis and revision of the manuscript. XZ, JW, and BD contributed to the data collection. SY and QD contributed to the study design and critical revision of the manuscript. All authors reviewed and approved the final manuscript.

Funding

The National Key R&D Program of China (2023YFC3604701, 2020YFC2008005, 2018YFC2002405); the Regional Innovation Cooperation Program of Science and Technology Commission Foundation of Sichuan Province (2021YFQ0031); the Sichuan Provincial Scientific Grant (2022YFS0354). The funders had no role in the study design or implementation; the data collection, management, analysis, and interpretation; the manuscript preparation, review, or approval; or the decision to submit the manuscript for publication.

Availability of data and materials

The datasets used and analyzed in this current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study received ethical approval from the institutional ethics review committee of West China Hospital (2017 – 303) and was registered at the Chinese Clinical Trial Registry (Registration Number: ChiCTR2100049973). All participants or their proxy respondents provided written informed consent. The research was performed in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. ²Institute for Disaster Management and Reconstruction, Sichuan University-The Hongkong Polytechnic University, Chengdu, Sichuan, China. ³West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. ⁴National Clinical Research Center for Geriatrics, Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China. ⁵School of Resource and Environmental Sciences, Wuhan University, Wuhan, China. ⁶International Institute of Spatial Lifecourse Health (ISLE), Wuhan University, Wuhan, China. ⁷West China Hospital of Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan, China.

Received: 12 March 2024 Accepted: 20 May 2024 Published online: 31 May 2024

References

- Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245–9.
- Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the american heart association. Circulation. 2021;143:e254-743.
- Fuster V. Changing demographics: a new approach to global health care due to the aging population. J Am Coll Cardiol. 2017;69:3002–5.
- Abdi S, Spann A, Borilovic J, de Witte L, Hawley M. Understanding the care and support needs of older people: a scoping review and categorisation using the WHO international classification of functioning, disability and health framework (ICF). BMC Geriatr. 2019;19:1–15.
- Lei P, Feng Z, Wu Z. The availability and affordability of long-term care for disabled older people in China: the issues related to inequalities in social security benefits. Arch Gerontol Geriatr. 2016;67:21–7.

- Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. New Engl J Med. 2008;358:1887–98.
- Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. New Engl J Med. 2015;373:2103–16.
- Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.
- Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.
- Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. New Engl J Med. 2021;385:1268–79.
- Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the US adult population. J Am Coll Cardiol. 2016;67:463–72.
- Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/A SPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–248.
- Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017;166:430–7.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.
- Molander L, Lövheim H, Norman T, Nordström P, Gustafson Y. Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc. 2008;56:1853–9.
- Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension. 2014;63:29–36.
- Lv YB, Gao X, Yin ZX, Chen HS, Luo JS, Brasher MS, et al. Revisiting the association of blood pressure with mortality in oldest old people in China: community based, longitudinal prospective study. BMJ. 2018;361:k2158.
- Masoli JAH, Delgado J, Pilling L, Strain D, Melzer D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing. 2020;49:807–13.
- Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med. 2012;172:1162–8.
- Feng Z, Glinskaya E, Chen H, Gong S, Qiu Y, Xu J, et al. Long-term care system for older adults in China: policy landscape, challenges, and future prospects. Lancet. 2020;396:1362–72.
- Bouwstra H, Smit EB, Wattel EM, van der Wouden JC, Hertogh CM, Terluin B, et al. Measurement properties of the Barthel Index in geriatric rehabilitation. J Am Med Dir Assoc. 2019;20:420–5.
- Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil. 1979;60:14–7.
- 24. Brusselaers N, Lagergren J. The Charlson comorbidity index in registrybased research. Method Inf Med. 2017;56:401–6.
- Zhang Y, Chen X, Wang Y, Shen Y, Dong B. Analysis of the reliability and validity of the disability assessment scale for the adult. J Sichuan Univ (Med Sci Ed). 2018;49:789–92.

- Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761–7.
- 27. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61:962–73.
- Lip S, Tan LE, Jeemon P, McCallum L, Dominiczak AF, Padmanabhan S. Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic. Hypertension. 2019;74:767–75.
- SCORE2 Working Group and ESC Cardiovascular Risk Collaboration HS, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439–54.
- Ogliari G, Westendorp RG, Muller M, Mari D, Torresani E, Felicetta I, et al. Blood pressure and 10-year mortality risk in the Milan geriatrics 75 + cohort study: role of functional and cognitive status. Age Ageing. 2015;44:932–7.
- Douros A, Tölle M, Ebert N, Gaedeke J, Huscher D, Kreutz R, et al. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin initiative study. Eur Heart J. 2019;40:2021–8.
- Angelini A, Trial J, Ortiz-Urbina J, Cieslik KA. Mechanosensing dysregulation in the fibroblast: a hallmark of the aging heart. Ageing Res Rev. 2020;63:101150.
- Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. 2015;175:989–95.
- Rea F, Cantarutti A, Merlino L, Ungar A, Corrao G, Mancia G. Antihypertensive treatment in elderly frail patients: evidence from a large Italian database. Hypertension. 2020;76:442–9.
- Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185–91.
- 36. Benetos A, Gautier S, Labat C, Salvi P, Valbusa F, Marino F, et al. Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE (predictive values of blood pressure and arterial stiffness in Institutionalized very aged Population) study. J Am Coll Cardiol. 2012;60:1503–11.
- Rådholm K, Festin K, Falk M, Midlöv P, Mölstad S, Östgren CJ. Blood pressure and all-cause mortality: a prospective study of nursing home residents. Age Ageing. 2016;45:826–32.
- Liu X, Steinman MA, Lee SJ, Peralta CA, Graham LA, Li Y, et al. Systolic blood pressure, antihypertensive treatment, and cardiovascular and mortality risk in VA nursing home residents. J Am Geriatr Soc. 2023;71:2131–40.
- Fan J, Yu C, Guo Y, Bian Z, Sun Z, Yang L, et al. Frailty index and all-cause and cause-specific mortality in Chinese adults: a prospective cohort study. Lancet Public Health. 2020;5:e650-660.
- Masoli JA, Delgado J, Pilling L, Strain D, Melzer D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing. 2020;49:807–13.
- Ravindrarajah R, Hazra NC, Hamada S, Charlton J, Jackson SHD, Dregan A, et al. Systolic blood pressure trajectory, frailty, and all-cause mortality > 80 years of age: cohort study using electronic health records. Circulation. 2017;135:2357–68.
- 42. Graham LA, Lee SJ, Steinman MA, Peralta CA, Rubinsky AD, Jing B. Exploring the dynamics of week-to-week blood pressure in nursing home residents before death. Am J Hypertens. 2022;35:65–72.
- Bulterijs S, Hull RS, Björk VC, Roy AG. It is time to classify biological aging as a disease. Front Genet. 2015;6:205.
- 44. Todd OM, Wilkinson C, Hale M, Wong NL, Hall M, Sheppard JP, et al. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing. 2019;48:627–35.
- Peralta CA, Katz R, Newman AB, Psaty BM, Odden MC. Systolic and diastolic blood pressure, incident cardiovascular events, and death in elderly persons: the role of functional limitation in the cardiovascular health study. Hypertension. 2014;64:472–80.
- Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394:1365–75.

- Aarts S, Patel KV, Garcia ME, Van den Akker M, Verhey FR, Metsemakers JF, et al. Co-presence of multimorbidity and disability with frailty: an examination of heterogeneity in the frail older population. J Frailty Aging. 2015;4:131–8.
- Zamudio-Rodríguez A, Letenneur L, Féart C, Avila-Funes JA, Amieva H, Pérès K. The disability process: is there a place for frailty? Age Ageing. 2020;49:764–70.
- Cicolini G, Pizzi C, Palma E, Bucci M, Schioppa F, Mezzetti A, et al. Differences in blood pressure by body position (supine, Fowler's, and sitting) in hypertensive subjects. Am J Hypertens. 2011;24:1073–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.